OVA Peptide(257-264)
Based on 22 publication(s) in Google Scholar
OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
For research use only. We do not sell to patients.
- Purity: 99.65%
- CAS No.: 138831-86-4
- Formula: C45H74N10O13
- Molecular Weight:963.13
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) OVA Peptide(257-264)
More- Signal Transduct Target Ther. 2026 Apr 28;11(1):156. [Abstract]
- Cancer Cell. 2026 Jun 11:S1535-6108(26)00257-6. [Abstract]
- Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
- Cancer Cell. 2025 Sep 8;43(9):1758-1775.e8. [Abstract]
- Cell. 2026 Jun 25;189(13):3922-3939.e20. [Abstract]
- Nat Commun. 2025 Sep 2;16(1):8181. [Abstract]
- Mol Cell. 2024 Mar 21;84(6):1120-1138.e8. [Abstract]
- Adv Sci (Weinh). 2026 Mar 13:e18525. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(45):e2404756. [Abstract]
- Biomaterials. 2025 Dec 18:329:123925. [Abstract]
- J Control Release. 2026 Jul 10:395:115032. [Abstract]
- Cell Death Dis. 2025 Jun 20;16(1):462. [Abstract]
- Cell Commun Signal. 2024 Aug 27;22(1):413. [Abstract]
- Mol Ther. 2026 Jun 2:S1525-0016(26)00470-3. [Abstract]
- J Med Chem. 2026 Apr 23;69(8):9603-9614. [Abstract]
- J Med Chem. 2026 Feb 26;69(4):4900-4912. [Abstract]
- OncoImmunology. 2022 Feb 9;11(1):2034257. [Abstract]
- Nutrients. 2024 Oct 22;16(21):3577. [Abstract]
- Pathol Res Pract. 2025 Apr 10:270:155975. [Abstract]
- bioRxiv. 2026 Apr 28.
- BIO Web of Conferences. 2025 Jul 2.
- bioRxiv. 2023 Jan 31.
Customer Validation & Images
-
Flow Cytometry
-
Cell Imaging/Staining
Biological Activity
TAP1-I- and C57BL/6 macrophages may process Crl-OVA and full-length OVA in different cellular compartments and that the protein context of the OVA Peptide(257-264) epitope influences the extent of TAP-independent processing for MHC class I presentation. OVA Peptide(257-264) epitope is presented with a differential dependence on the TAP transporter depending on the protein context of the OVA epitope: OVA Peptide(257-264) contained within the MBPCrl-OVA or Crl-OVA bacterial fusion proteins is presented with little dependence on the TAP transporter, while OVA Peptide(257-264) contained within full-length ovalbumin is largely dependent on the TAP transporter, regardless of whether recombinant OVA is expressed in bacteria or the native protein is coupled to polystyrene beads[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 138831-86-4
-
Appearance Solid
-
Molecular Weight 963.13
-
Formula C45H74N10O13
-
Color White to off-white
-
Sequence
Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu
-
Sequence Shortening
SIINFEKL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. [Abstract]2026 Apr 28;11(1):156. PMID: 42045172 -
Cancer Cell
Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. [Abstract]2026 Jun 11:S1535-6108(26)00257-6. PMID: 42276047 -
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606 -
Cancer Cell
DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. [Abstract]2025 Sep 8;43(9):1758-1775.e8. PMID: 40816293 -
Cell
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. [Abstract]2026 Jun 25;189(13):3922-3939.e20. PMID: 42102817 -
Nat Commun
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. [Abstract]2025 Sep 2;16(1):8181. PMID: 40897711 -
Mol Cell
2024 Mar 21;84(6):1120-1138.e8. PMID: 38377992 -
Adv Sci (Weinh)
Context-Dependent Role of GDF15: GDF15+ Tumor-Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis. [Abstract]2026 Mar 13:e18525. PMID: 41824793 -
Adv Sci (Weinh)
ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages. [Abstract]2024 Dec;11(45):e2404756. PMID: 39377228 -
Biomaterials
2025 Dec 18:329:123925. PMID: 41453350 -
J Control Release
STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves. [Abstract]2026 Jul 10:395:115032. PMID: 42155600 -
Cell Death Dis
ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma. [Abstract]2025 Jun 20;16(1):462. PMID: 40541964 -
Cell Commun Signal
Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2. [Abstract]2024 Aug 27;22(1):413. PMID: 39192276 -
Mol Ther
Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness. [Abstract]2026 Jun 2:S1525-0016(26)00470-3. PMID: 42231576 -
J Med Chem
Dual-Functional Anti-SIRPα-cGAMP Conjugate Reprograms the Tumor Immune Microenvironment and Enhances Antitumor Immunity. [Abstract]2026 Apr 23;69(8):9603-9614. PMID: 41918375 -
J Med Chem
Modulation of Tumor Microenvironment via Antibody Mediated Precision Delivery of CpG to Myeloid Cell. [Abstract]2026 Feb 26;69(4):4900-4912. PMID: 41649040 -
OncoImmunology
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer. [Abstract]2022 Feb 9;11(1):2034257. PMID: 35154907 -
Nutrients
Effect of Nicotinamide Riboside Against the Exhaustion of CD8+ T Cells via Alleviating Mitochondrial Dysfunction. [Abstract]2024 Oct 22;16(21):3577. PMID: 39519411 -
Pathol Res Pract
SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion. [Abstract]2025 Apr 10:270:155975. PMID: 40228401 -
-
OVA Peptide(257-264) purchased from MedChemExpress. Usage Cited in: BIO Web of Conferences. 2025 Jul 2.
OT-1 CD8+ T cells were stimulated with OVA Peptide(257-264) TFA (SIINFEKL peptide) (1 ug/mL; 24-48 h) and sampled for CFSE detection via flow cytometry.
OVA Peptide(257-264) purchased from MedChemExpress. Usage Cited in: BIO Web of Conferences. 2025 Jul 2.
B16F10-FLuc cells were pre-treated with/without OVA Peptide(257-264) TFA (SIINFEKL peptide) (25 nM; 2 h) and then co-cultured with OT-1 CD8+ T cells for 4 h. Luminescence was measured by mixing 50 μL of supernatant with 100 μL of luciferase substrate.
-
Solvent & Solubility
DMSO : 20 mg/mL (20.77 mM; ultrasonic and adjust pH to 2 with 1 M HCL; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
0.1% TFA in Water : 1.83 mg/mL (1.90 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
TAPl-/- or C57BL/6 macrophages are co-incubated with either bacteria or polystyrene beads containing the 257-264 epitope from ovalbumin [OVA Peptide(257-264)], which binds the mouse class I molecule Kb. The source of the OVA(257-264) epitope is either the Crl-OVA(257-264) (Crl-OVA) fusion protein, the maltose binding protein (MBP)-Crl-OVA fusion protein, native OVA or bacterial recombinant OVA (rOVA); Crl-OVA, MBP-Crl-OVA and rOVA are each expressed in bacteria, and Crl-OVA and MBP-Crl-OVA purified from bacterial lysates and native egg OVA are coated onto polystyrene beads[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| 0.1% TFA in Water / DMSO | 1 mM | 1.0383 mL | 5.1914 mL | 10.3828 mL | 25.9570 mL |
| DMSO | 5 mM | 0.2077 mL | 1.0383 mL | 2.0766 mL | 5.1914 mL |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL | 2.5957 mL | |
| 15 mM | 0.0692 mL | 0.3461 mL | 0.6922 mL | 1.7305 mL | |
| 20 mM | 0.0519 mL | 0.2596 mL | 0.5191 mL | 1.2979 mL |
OVA Peptide(257-264) Related Classifications
HY-P1489 Related Classifications
Powered by Bioz